|
|
Saturday, May 5, 2012 ■ GYNECOLOGY
| |
|
|
|
SAFETY OF ORAL CONTRACEPTION: TIME TO LOOK AGAIN AT THE EVIDENCE
Capsule: First and foremost, a discussion of contraceptive safety is perhaps the hottest topic today
Chairperson: F. Martinez, Spain; H. Coelingh Bennink, The Netherlands |
HALL A | |
| 08:30-09:00 |
New generation oral contraceptive pills: Are they safe? |
|
L. Shulman, USA |
|
Debate: Progesterone only contraception, better or worse? |
| 09:00-09:30 |
For: G. Merki-Feld, Switzerland |
| 09:30-10:00 |
Against: T. Bombas, Portugal |
|
|
| 10:00-10:30 |
Coffee Break at the exhibition |
|
|
|
|
|
NEW DEVELOPMENT AND A WINDOW TO A NEW FORMULA: WHO WOULD BENEFIT FROM IT?
Capsule: new estrogen and progestines are penetrating the market. Is there a real need for it?
Chairperson:S. Skouby, Denmark; J. Bitzer, Switzerland |
HALL A | |
| 10:30-11:00 |
Estetrol for Oral Contraception – are we facing a safer formulation?
H. Coelingh Bennink, The Netherlands |
|
11:00-11:30 |
NOMAC/E2: The next generation of oral contraception?
J. Bitzer, Switzerland |
| 11:30-12:30 |
Debate: Emergency contraception: What should be used? |
|
Ulipristal acetate vs. Levonorgestrel for emergency contraception: A. Ber, Israel |
|
Short acting GnRH antagonist: Z. Shoham, Israel |
|
IUD: A neglected option: F. Martinez, Spain |
| 12:30-13:00 |
LUNCH at the exhibition |
|
|
Symposium:
HOT TOPICS
Chairpersons: Z. Shoham, Israel, M. Hod, Israel |
|
13:00-13:25
13:25-13:50
13:50-14:00
|
|
Making human ova from Stem Cells
E. Telfer, Scotland
Does the risk of congenital malformation vary by mode of infertility treatment?
M. Davies, Australia
__________________________________________________________________
Abbott's award for best abstracts | |
|
|
|
WHI DATA THROUGH THE MAGNIFYING GLASS: A DECADE-LONG DEBATE
Organized by IMS & in collaboration with EMAS & APMF
Chairpersons: T. de Villiers, South Africa; A. Pines, Israel |
HALL A | |
| 14:00-14:30 |
Strengths and weaknesses of WHI: Methodological perspectives
R. Langer, USA |
| 14:30-15:00 |
Recent guidelines and recommendations on hormone replacement therapy
T. de Villiers, South Africa |
| 15:00-16:00 |
Panel Discussion: Has the time come to reach a consensus on hormone replacement therapy?
Delegates from the major menopause societies, aiming at defining the aspects which are globally agreed and the still existing un-bridged issues. Iit will be divided into chapters with separate discussions, such as on indications, length of Tx, low-dose, E-only, Tx of early menopause, risks of Tx, development of treatment algorhithms.
T. de Villiers, South Africa (IMS)
F.O. Liew, Malaysia (APMF)
S. Palacios, Spain
S. Rozenberg, Belgium (EMAS) |
|
|
|
16:00-16:30 |
Coffee Break the exhibition |
|
|
|
16:30-18:00 |
|
HORMONE REPLACEMENT THERAPY: PERSPECTIVES OF 2012
Organized by IMS & in collaboration with EMAS & APMF & partially supported by Besins Healthcare
Chairpersons: S. Rozenberg, Belgium; A. Pines, Israel |
HALL A | |
| 16:30-16:50 |
A world without hormone replacement therapy, fact or fiction?
S. Rozenberg, Belgium |
| 16:50-17:10 |
Breast cancer risk strikes out hormone replacement therapy
A. Gompel, France |
| 17:10-18:00 |
Debate: Back to oestrogen-only therapy? |
|
Pro: M. Birkhäuser, Switzerland |
|
Con: J. Stevenson, UK |
|
|
|
Saturday, May 5, 2012 ■ PERINATOLOGY
|
|
|
|
CONTROVERSIES TO CONSENSUS
HOT TOPICS IN PERINATAL MEDICINE: PET AND FETAL CONGENITAL ANOMALIES
Chairperson: I. Meizner, Israel; L. Cabero, Spain |
HALL B | |
| 08:30-09:10 |
Debate: Routine fetal anomaly screening in the first, second and third trimesters of all pregnancies? |
|
One anomaly scan is adequate: K. Bilardo, The Netherlands |
|
Three anomaly scans are the ideal way to examine the fetus: Y. Zalel, Israel |
|
Routine transvaginal scan at 20 weeks?: E. Carreras Moratonas, Spain |
| 09:10-09:30 |
Discussion |
|
Moderator: I. Meizner, Israel |
| 09:30-09:50 |
Debate: Prediction and prevention of preeclampsia |
|
Yes: Prediction and prevention is possible: H. Valensise, Italy |
|
No: Preeclampsia is unpredictable: F. Figueras, Spain |
| 09:50-10:10 |
Discussion |
|
Moderator: L. Cabero, Spain |
| 10:10-10:30 |
Chairperson’s overview: Towards a consensus |
|
|
| 10:00-10:30 |
Coffee Break at the exhibition |
|
|
|
|
|
CONTROVERSIES TO CONSENSUS: HOT TOPICS IN MATERNAL FETAL MEDICINE
All you can get on FGR
Chairperson: A. Wiznitzer, Israel; G. Visser, The Netherlands |
HALL B | |
| 10:30-10:45 |
Developmental origins of adult disease: Impact on perinatal medicine
U. Simeoni, France |
| 10:45-11:00 |
The definition and diagnosis of SGA
G. Visser, The Netherlands |
| 11:00-11:15 |
Is IUGR predictable and preventable?
M. Ben-Ami, Israel |
| 11:15-11:30 |
Early versus late onset FGR: Are they different?
E. Gratacós, Spain |
| 11:30-11:45 |
FGR remote from term/near term: Delivery vs. Expectant management
N. Melamed , Israel |
|
11:45-12:00
12:00-12:30 |
Should genetic counseling be part of the diagnostic work up near term?
T. H. Bui, Sweden
Q&A |
|
12:30-13:00
|
LUNCH at the exhibition
|
|
13:00-13:50 |
Symposium: (HALL A)
HOT TOPICS |
|
13:00-13:25
13:25-13:50
13:50-14:00
|
Making human ova from Stem Cells
E. Telfer, Scotland
Does the risk of congenital malformation vary by mode of infertility treatment?
M. Davies, Australia
_____________________________________________________________________
Abbott's award for best abstracts (HALL A) |
|
|
|
THE PERINATAL TRIBUNAL
PROCESSING THE NOVEL APPROACH TO DIABETIC PREGNANCY
The Honorable Judge: M. Hod, Israel; H. Valensise, Italy |
HALL B | |
|
GDM diagnosis
Case 1: Gestational diabetes is over diagnosed and over treated
|
| 14:00-14:10 |
Yes: It's over diagnosed and over treated: R. Corcoy, Spain |
| 14:10-14:20 |
No: It's NOT over diagnosed and over treated: D. McIntyre, Australia |
|
Court appointed expert: A. Kapur, Denmark |
|
Treatment during pregnancy
Case 2: Can oral hypoglycaemic agents be used throughout pregnancy? |
| 14:20-14:30 |
The Defence: Yes, OHA can be used: Y. Yogev, Israel |
| 14:30-14:50 |
The Prosecution: No, OHA cannot be used: A. Lapolla, Italy |
|
Court appointed expert: N. Lohse, Denmark |
| 14:50-15:20 |
State of the art lecture: The use of insulin analogues in diabetic pregnancy
M. Hod, Israel |
|
Delivery
Case 3: Should we deliver all diabetic patients by CS? Is there an estimated fetal weight cut off? |
| 15:20-15:30 |
Yes: S. Alberico, Italy |
| 15:30-15:40 |
No: G. Visser, The Netherlands |
|
Court appointed expert: A. Antsaklis, Greece |
| 15:40-16:00 |
Discussion |
|
The Jury: Congress Participants |
|
The Verdict: The Honourable Judges |
|
|
| 16:00-16:30 |
Coffee Break at the exhibition |
|
|
|
|
|
CONTROVERSIES TO CONSENSUS: NOVEL APPROACH TO MULTIPLE PREGNANCIES
Chairpersons: E. Gratacós, Spain; G. Visser, The Netherlands |
HALL B | |
| 16:30-16:45 |
MC twins: Should termination be offered?
I. Blickstein, Israel |
| 16:45-17:00 |
Reduction from twins to singleton (MC and DC)?
M. Evans, USA |
| 17:00-17:15 |
Management of growth restriction in MC pregnancy
E. Gratacós, Spain |
| 17:15-17:30 |
The risk of perinatal complications in DC twins
E. Llurba, Spain |
| 17:30-17:50 |
Debate: How and when to deliver MC and BC twins?
Moderators: E. Gratacós, Spain; G. Visser, The Netherlands |
|
I. Blickstein, Israel |
|
M. Evans, USA |
|
E. Gratacós, Spain |
|
E. Llubra, Spain |
| 17:50-17:55 |
Discussion |
| 17:55-18:00 |
Chairperson's overview: Towards a consensus |
|
|
|
Saturday, May 5, 2012 ■ REPRODUCTIVE MEDICINE & ART
|
|
|
|
PRE-CONCEPTION GENETIC DIAGNOSIS AND PGD
Capsule: Advances in genomics currently allow for the screening of hundreds of genetic diseases. This may allow us to eliminate the risk for most inherited diseases but also makes very easy the selection of other traits.
Chairperson: S. Munné, USA |
HALL C | |
| 08:30-09:00 |
Preconception genetics for IVF patients and gamete donation
S. Munné, USA |
| 09:00-10:00 |
Debate: European for PBs, USA for blastocysts
Preconception genetic diagnosis followed by PGD are the right time to screen for genetic diseases, and not prenatal diagnosis
M. Hughes, USA
Whole genome sequencing is easy – but who will make sense of it?
Mark Evans, USA
Does PGS increase live birth rate? The pendulum of PGS
S. Fishel, UK |
|
10:00-10:30 |
Coffee Break at the exhibition |
|
|
|
|
LUTEAL PHASE SUPPORT
Chairpersons: R. Aurell, Spain; A. Weissman, Israel |
| 10:30-11:00 |
Overview of the luteal phase with emphasis on early introduction of progesterone
TBA |
| 11:00-12:00 |
Debate: What should be the preferred route for progesterone administration? |
|
IM route: N. Gleicher, USA |
|
Vaginal products: TBA |
| 12:00-12:30 |
Estrogen and GnRH agonists for luteal support
G. Grudzinskas, UK |
| 12:30-13:00 |
LUNCH at the exhibition |
|
13:00-13:50 |
Symposium: (HALL A)
HOT TOPICS |
|
13:00-13:25
13:25-13:50
13:50-14:00
|
|
Making human ova from Stem Cells
E. Telfer, Scotland
Does the risk of congenital malformation vary by mode of infertility treatment?
M. Davies, Australia
_____________________________________________________
Abbott's award for best abstracts (HALL A) | |
|
|
|
IVM
Capsule: Is it still an experimental procedure? Why has it not become common practice in IVF?
Chairpersons: M. Leong, China; G. Schatten, USA |
HALL C | |
| 14:00-15:00 |
Debate |
|
IVM as an alternative to FSH IUI for treatment of infertility: S.L. Tan, Canada |
|
IVM for selected group of patients only: M. Leong, China |
| 15:00-15:30 |
Oocytes generated in vitro: What are the strengths and limitations of artificial gametes?
G. Schatten, USA |
| 15:30-16:00 |
Is there an optimal stimulation protocol? Optimal number of oocytes to achieve a pregnancy
P. Barri, Spain |
|
|
| 16:00-16:30 |
Coffee Break at the exhibition |
|
|
|
|
|
HOW SHOULD WE EVALUATE THE OOCYTE DURING ART?
Chairpersons: I. Tur-Kaspa, USA |
HALL C | |
| 16:30-17:00 |
Oocyte competence for fertilization: What are the events vital to complete maturation?
G. Schatten, USA |
| 17:00-17:30 |
Predicting oocyte competence by polar body chromosome analysis
S. Fishel, UK |
| 17:30-18:00 |
The follicle and oocyte competence: Does size or volume matter?
A. Revelli, Italy |
|
|
|
|
|
|
WebStudio.co.il
